[go: up one dir, main page]

UY28367A1 - Agentes terapéuticos - Google Patents

Agentes terapéuticos

Info

Publication number
UY28367A1
UY28367A1 UY28367A UY28367A UY28367A1 UY 28367 A1 UY28367 A1 UY 28367A1 UY 28367 A UY28367 A UY 28367A UY 28367 A UY28367 A UY 28367A UY 28367 A1 UY28367 A1 UY 28367A1
Authority
UY
Uruguay
Prior art keywords
ethyl
therapeutic agents
dyslipidemias
oxyl
manifestations
Prior art date
Application number
UY28367A
Other languages
English (en)
Inventor
Matti Ahlqvist
Martin Hans Bohlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28367A1 publication Critical patent/UY28367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/06—Potassium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una sal de potasio o una sal de sodio del ácido (-)-2-((2-(4-hidroxifenil)etil)tio)-3-(4-(2-(4-((metilsulfonil)oxil)fenoxi)etil)fenil)propanoico, procesos para su `preparación, su uso en el tratamiento de trastornos clínicos incluidos trastornos lipídicos (dislipidemias) asociadas o no con la resistencia a la insulina y otras manifestaciones del síndrome metabólico, y composiciones farmacéuticas que las contengan
UY28367A 2003-06-18 2004-06-17 Agentes terapéuticos UY28367A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314131.4A GB0314131D0 (en) 2003-06-18 2003-06-18 Therapeutic agents
PCT/GB2004/002595 WO2004113284A1 (en) 2003-06-18 2004-06-16 Potassium or sodium salt of (-)-2-{`2-(4-hydroxyphenyl)ethyl!-thio-3-`4-(2-{4-`(methzlsulfonzl) oxy !phenoxy}phenyl!propanoic acid and their use in medicine

Publications (1)

Publication Number Publication Date
UY28367A1 true UY28367A1 (es) 2005-01-31

Family

ID=27636790

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28367A UY28367A1 (es) 2003-06-18 2004-06-17 Agentes terapéuticos

Country Status (20)

Country Link
US (1) US20070099997A1 (es)
EP (1) EP1641749A1 (es)
JP (1) JP2006527750A (es)
KR (1) KR20060026427A (es)
CN (1) CN1835920A (es)
AR (1) AR044800A1 (es)
AU (1) AU2004249485A1 (es)
BR (1) BRPI0411515A (es)
CA (1) CA2529251A1 (es)
CO (1) CO5650240A2 (es)
GB (1) GB0314131D0 (es)
IL (1) IL172440A0 (es)
IS (1) IS8234A (es)
MX (1) MXPA05013826A (es)
NO (1) NO20055927L (es)
RU (1) RU2005141068A (es)
TW (1) TW200503679A (es)
UY (1) UY28367A1 (es)
WO (1) WO2004113284A1 (es)
ZA (1) ZA200510196B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
DK1517883T3 (da) 2002-06-20 2008-05-26 Astrazeneca Ab Ortho-substituerede benzoesyrederivater til behandling af insulinresistens
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0427524D0 (en) 2004-12-16 2005-01-19 Astrazeneca Ab Chemical process

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
SE0000772D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
WO2003022286A1 (en) * 2001-09-08 2003-03-20 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
SE0104333D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
BRPI0411515A (pt) 2006-08-01
IS8234A (is) 2006-01-16
NO20055927L (no) 2006-01-27
CA2529251A1 (en) 2004-12-29
US20070099997A1 (en) 2007-05-03
CN1835920A (zh) 2006-09-20
EP1641749A1 (en) 2006-04-05
WO2004113284A1 (en) 2004-12-29
AR044800A1 (es) 2005-10-05
RU2005141068A (ru) 2007-07-27
IL172440A0 (en) 2006-04-10
AU2004249485A1 (en) 2004-12-29
CO5650240A2 (es) 2006-06-30
JP2006527750A (ja) 2006-12-07
MXPA05013826A (es) 2006-02-28
GB0314131D0 (en) 2003-07-23
TW200503679A (en) 2005-02-01
KR20060026427A (ko) 2006-03-23
ZA200510196B (en) 2006-12-27

Similar Documents

Publication Publication Date Title
UA100966C2 (ru) Фармацевтическая композиция на основе 2-[4-(4-хлорбензоил)фенокси]-2-метилпропионовой кислоты и ее солей
GT200300075AA (es) Compuestos que modulan la actividad ppar y procedimientos para su preparacion (patente fraccionaria no. 1 de la solicitud no. pi-20030075)
EA200970791A1 (ru) N-АДАМАНТИЛБЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ
CL2007001873A1 (es) Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
BRPI0515946A (pt) sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
AR054261A1 (es) Sales fisiologicamente compatibles de ester etilico del acido 3-(2-{(4-(hexiloxicarbonilamino-imino-metil )-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propionico, composiciones farmaceuticas que las contienen y su uso en la preparacion de un medicamento para la profil
AR029412A1 (es) Forma cristalina
PE20140572A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
PE20120642A1 (es) Formulacion en lipidos estabilizada de un promotor de la apoptosis
BRPI0706992C8 (pt) composto de fórmula (i) e formulação farmacêutica
BR112017007720A2 (pt) preparação compósita contendo derivado de ácido 3-(4-(benzilóxi)fenil)hex-4-inoico e outro princípio ativo para prevenir ou tratar doenças metabólicas
AR029456A1 (es) Forma triturada
Yadav et al. Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double-blind trial
AR064702A1 (es) Agonistas de receptores de proteina g heterociclicos, una composicion farmaceutica que los comprende y su uso en el tratamiento de la diabetes y trastornos metabolicos.
UY28367A1 (es) Agentes terapéuticos
AR093188A1 (es) Sal y uso medico
UY28372A1 (es) Agentes terapéuticos
PE20100467A1 (es) Compuesto mono-l-malato (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y composiciones que lo contienen
AR044802A1 (es) Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos
AR051998A1 (es) Agentes terapeuticos
UY29272A1 (es) Agentes terapeuticos
DOP2006000018A (es) Formulaciones y regimen de dosificación para moduladores alfa de ppar
AR003093A1 (es) Nuevos derivados de imidazol-n-bencildioxol, su procedimiento de preparacion, su aplicacion a titulo de medicamentos, composicionesfarmaceuticas y nueva utilizacion.
AR083893A1 (es) Uso de una composicion farmaceutica que comprende (s) (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol para preparar un medicamento topico de utilidad en la reduccion de la presion intraocular y articulo de manufactura correspondiente
CL2004000726A1 (es) Compuestos derivados de 4-[2-(feniloxi sustituido)fenil]piperidina o -1,2,3,6-tetrahidropiridina; composcion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansi

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150602